SCHEMBL222039

SCHEMBL222039

[c]1c2c(nc3ccccc13)CNCC2

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 2/20 0.37
TNKS2 Q9H2K2 1/20 0.37
PARP2 Q9UGN5 1/20 0.37
HTR2C P28335 2/20 0.37
PNMT P11086 1/20 0.35
CD44 P16070 1/20 0.35
MAOB P27338 1/20 0.35
MAPT P10636 1/20 0.34
CYP3A4 P08684 2/20 0.33
APEX1 P27695 1/20 0.32
KDM4E B2RXH2 2/20 0.32
HTR5A P47898 1/20 0.32
NISCH Q9Y2I1 1/20 0.32
NR2E1 Q9Y466 1/20 0.32
PDCD1 Q15116 1/20 0.32
CD274 Q9NZQ7 1/20 0.32
BCHE P06276 5/20 0.31
ACHE P22303 5/20 0.31
ALDH1A1 P00352 2/20 0.31
TSHR P16473 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL223109 0.87 MAPT (0.36) PARP1TNKS2PARP2HTR2CPNMT
SCHEMBL223760 0.85 TDP1 (0.30) MAPTCYP3A4KDM4EBCHEACHE
SCHEMBL4909847 0.76 BCHE (0.45) CYP3A4KDM4EBCHEACHEALDH1A1
SCHEMBL1532144 0.76 BCHE (0.45) CYP3A4KDM4EBCHEACHEALDH1A1
SCHEMBL4464318 0.75 BCHE (0.46) CYP3A4KDM4EBCHEACHEALDH1A1
SCHEMBL6312249 0.73 HTR2C (0.47) PARP1TNKS2PARP2HTR2CPNMT
SCHEMBL222040 0.67 HTR2C (0.49) PARP1TNKS2PARP2HTR2CPNMT
SCHEMBL9170695 0.67 ACHE (0.62) CYP3A4KDM4EBCHEACHEALDH1A1
SCHEMBL6313436 0.67 HTR2C (0.48) PARP1TNKS2PARP2HTR2CMAPT
SCHEMBL23981 0.65 MAPT (0.56) MAOBMAPTKDM4EACHEALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240156742-A1 TARGETED MULTIFUNCTIONAL NANOSTRUCTURED LIPID CARRIERS TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) 2024-05-16 US disclosed
US-20240148886-A1 INTRACELLULAR DELIVERY COMPOSITIONS BIOND BIOLOGICS LTD. (IL) 2024-05-09 US disclosed
US-20240025886-A1 INHIBITORS OF IGF2BP1-RNA BINDING YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) 2024-01-25 US disclosed
US-20230201201-A1 COMPOSITION FOR USE IN THE TREATMENT OF APOL1-ASSOCIATED DISEASE TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) 2023-06-29 US disclosed
WO-2023112038-A1 NEUTROPHIL EXOCYTOSIS INHIBITORS IMMUNYX PHARMA LTD. (IL) 2023-06-22 WO disclosed
US-20230124527-A1 NANOPARTICLES FOR CHEMIRESISTOR SENSORS NANOSCENT LTD. (IL) 2023-04-20 US disclosed
US-20230104413-A1 NANOPARTICLES FOR CHEMIRESISTOR SENSORS NANOSCENT LTD. (IL) 2023-04-06 US disclosed
US-11358931-B2 Selective androgen receptor modulators (SARMs) and uses thereof LIGAND PHARMACEUTICALS INCORPORATED (US) 2022-06-14 US disclosed
EP-4004127-A1 COATING COMPOSITIONS WITH POLYSILOXANE-MODIFIED CARBON NANOPARTICLE Valfre' di Bonzo, Roberto (CH) 2022-06-01 EP disclosed
US-11307158-B1 Nanoparticles for chemiresistor sensors NANOSCENT LTD. (IL) 2022-04-19 US disclosed
US-20090311237-A1 Combination therapy using a soluble hyaluronidase and a bisphosphonate HALOZYME THERAPEUTICS, INC. 2009-12-17 US disclosed
WO-2009128918-A1 COMBINATION THERAPY USING A SOLUBLE HYALURONIDASE AND A BISPHOSPHONATE HALOZYME, INC. (US) 2009-10-22 WO disclosed
US-7582794-B2 Process for the preparation of substituted 2-(phenoxymethyl)benzoic acids SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2009-09-01 US disclosed
WO-2009009117-A2 CHEMOENZYMATIC PROCESSES FOR PREPARATION OF LEVETIRACETAM BIOVERDANT, INC. (US) 2009-01-15 WO disclosed
EP-1699748-B1 METHOD FOR THE PRODUCTION OF SUBSTITUTED 2-(PHENOXYMETHYL)-BENZOIC ACIDS SANOFI AVENTIS DEUTSCHLAND (DE) 2008-10-15 EP disclosed
US-20070219395-A1 PROCESS FOR THE PREPARATION OF SUBSTITUTED 2-(PHENOXYMETHYL)BENZOIC ACIDS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-09-20 US disclosed
US-7238835-B2 Process for the preparation of substituted 2-(phenoxymethyl) benzoic acids SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-07-03 US disclosed
EP-1699748-A2 METHOD FOR THE PRODUCTION OF SUBSTITUTED 2-(PHENOXYMETHYL)-BENZOIC ACIDS Sanofi-Aventis Deutschland GmbH (DE) 2006-09-13 EP disclosed
US-20050171205-A1 Process for the preparation of substituted 2-(phenoxymethyl) benzoic acids AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2005-08-04 US disclosed
WO-2005061427-A2 METHOD FOR THE PRODUCTION OF SUBSTITUTED 2-(PHENOXYMETHYL)-BENZOIC ACIDS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2005-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230201201-A1 COMPOSITION FOR USE IN THE TREATMENT OF APOL1-ASSOCIATED DISEASE APOL1, APOB, LIPA PARP1 3888/4885TNKS2 3913/4885PARP2 3778/4885
US-20070219395-A1 PROCESS FOR THE PREPARATION OF SUBSTITUTED 2-(PHENOXYMETHYL)BENZOIC ACIDS CYP2B6, CYP1B1, CYP4B1 PARP1 1786/4885TNKS2 1678/4885PARP2 569/4885
US-20240156742-A1 TARGETED MULTIFUNCTIONAL NANOSTRUCTURED LIPID CARRIERS LCAT, CD47, PHOSPHO1 PARP1 2883/4885TNKS2 2108/4885PARP2 2938/4885
US-20240148886-A1 INTRACELLULAR DELIVERY COMPOSITIONS ACTB, CHERP, EEA1 PARP1 2910/4885TNKS2 1919/4885PARP2 2651/4885
US-20050171205-A1 Process for the preparation of substituted 2-(phenoxymethyl) benzoic acids CYP2B6, CYP1B1, CYP4B1 PARP1 1786/4885TNKS2 1678/4885PARP2 569/4885
US-11358931-B2 Selective androgen receptor modulators (SARMs) and uses thereof AR, NR5A1, SHBG PARP1 2979/4885TNKS2 2196/4885PARP2 3153/4885
US-20240025886-A1 INHIBITORS OF IGF2BP1-RNA BINDING IGF2BP1, IGF2BP2, IGF2BP3 PARP1 1364/4885TNKS2 2575/4885PARP2 1952/4885
US-20090311237-A1 Combination therapy using a soluble hyaluronidase and a bisphosphonate HEXD, BPGM, HEXA PARP1 2467/4885TNKS2 2708/4885PARP2 2261/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.